INTRODUCTION {#sec1-1}
============

Coronary angioplasty has successfully reduced the numbers of patients requiring coronary artery bypass graft surgery.\[[@ref1][@ref2]\] However, recurrent disease or restenosis has been reported to occur in 15%--40% of cases after angioplasty.\[[@ref3][@ref4]\] Despite the placement of a stent following angioplasty, in-stent restenosis (ISR) remains an important clinical problem in interventional cardiology, with a prevalence of 15%--27%.\[[@ref5][@ref6]\]

Angiographic restenosis is defined by stenosis of \>50% of the lumen of the artery, usually several months after percutaneous coronary intervention (PCI). Clinical stenosis is defined by the return of angina pectoris and the need for revascularization. Approximately, half of the patients who have angiographic restenosis do not have clinical symptoms.\[[@ref7][@ref8][@ref9]\]

Approximately \$1.6 billion per annum is spent for the treatment of restenosis in the US.\[[@ref10]\] Because of the cost and complexity of repeated angioplasty, identifying those at risk of restenosis may be of clinical utility, by allowing the selection of the best management, for example, the use of drug-eluted stents exclusively or coronary artery bypass surgery.\[[@ref10][@ref11]\]

Most previous studies have investigated the use of biomarkers, clinical characteristics, and procedural aspects of angioplasty, but these have failed to identify high-risk individuals, apart from the presence of diabetes mellitus and multiple coronary artery disease. It is possible that genetic factors play an important role in restenosis.\[[@ref12][@ref13]\]

The insertion of stent in coronary artery induces an inflammation response. A systematic review analyzed the pathways of genes associated with restenosis (derived from genome-wide association studies \[GWAS\]) and revealed that 50% of these pathways were associated with inflammation, 25% related to proliferation, and 10% related to vascular function.\[[@ref14]\]

Considering the likely importance of inflammation in restenosis, the goal of this current study was to investigate the frequency of polymorphisms of genes (interleukin 10 \[IL-10\], tumor necrosis factor-alpha \[TNFα\], annexin A5 \[ANXA5\]) that are involved in this process and were related to restenosis in GWAS or candidate gene studies.

Identification of risk factors associated with restenosis is useful in risk assessment of these patients and may also help to selection tailored therapy.

MATERIALS AND METHODS {#sec1-2}
=====================

Study design and population {#sec2-1}
---------------------------

In this case--control study, 306 unrelated Iranian patients who underwent elective PCI from Isfahan province were recruited between December 2014 and April 2017. The Scientific Ethics Committee of the Medical University of Mashhad, Iran, approved the study protocol (2015/930834), and all patients provided written informed consent.

The criteria used for selection of patients were as follows: patients were referred for re-angiography because of chest pain, equivalent symptoms such as dyspnea on exertion, and positive results of noninvasive cardiac tests after angioplasty. Based on the results of angiography, 104 patients who had \>50% stenosis within an implanted stent between 1 month and 1 year after angioplasty (restenosis interval) were placed in the ISR group and 202 patients who had no in-stent stenosis or ≤50% stenosis in implanted stent were placed in the non-ISR (NISR) control group.

Demographic data including sex, age, smoking history, drug history, history of diabetes, hypertension, dyslipidemia, blood pressure, body weight, and height were collected from medical records. Patients with primary PCI, restenosis in the 1^st^ month after angioplasty due to thrombosis, autoimmune disorder, active cancer, thrombophilia, or chronic kidney disease were excluded from the study.

Blood samples were taken before the procedure into ethylenediaminetetraacetic acid (EDTA) tubes for DNA extraction and into a tube with no anticoagulant for biochemistry markers.

Serum was separated by centrifuging the blood for 15 min at 1000 rpm speed (manufacturer\'s recommended speed). Serum was stored at −80°C and serum high-sensitivity C-reactive protein (hs-CRP) was measured using an enzyme immunoassay kit purchased from Diagnostics Biochem Canada Inc. Fasting blood glucose (FBG), triglycerides (TGs), total cholesterol (TC), and high-density lipoprotein were measured using Pars Azmoon kits on BT-3000 autoanalyzer. Low-density lipoprotein was calculated using the Friedewald formula.

Body mass index (kg/m^2^) was calculated by dividing the weight (kg) on square of the body height (m).

Genotyping {#sec2-2}
----------

DNA was extracted from EDTA blood, using a genomic DNA isolation kit (Genet bio, Korea) based on the manufacturer\'s instructions. Purity and DNA quantification were recognized by ultraviolet spectrophotometry (Infinite 200 PRO NanoQuant, Tecan).

We genotyped single-nucleotide polymorphisms (SNPs) of three genes: *IL-10, TNFα*, and *ANXA5* using real-time polymerase chain reaction (PCR) and high-resolution melting (HRM) assay (Light Cycler 96 System, Roche, Germany). We used "no template" controls to evaluate the contamination. The condition for real-time PCR and HRM was as follows: preincubation 1 Cycles: 95°C for 900 s; 3 Step amplification, 45 Cycles: 95°C for 15 s, 60°C for 20 s, 72°C for 20 s; HRM, 1 Cycles: 95°C for 60 s, 40°C for 60 s, 65°C for 1 s, 97°C for 1 s continuous; cooling, 1 Cycles: 40°C for 10 s.

We confirmed genotyping by sequencing of 10% of the templates. Data were analyzed using Light Cycler 96 System, Roche, Germany, Application Software.

Statistical analysis {#sec2-3}
--------------------

Chi-square tests were used to assess agreement of genotypes with the Hardy--Weinberg equilibrium. The association between *IL-10, TNFα*, and *ANXA5* polymorphisms and restenosis was calculated by the odds ratio (OR) with 95% confidence interval (CI).

Continuous variables were reported as mean ± standard deviation and categorical variables were expressed as percentage. Univariate and multivariate analysis was done with binary logistic regression and was expressed in OR (95% CI). All analyses were performed by the SPSS software (Chicago, IL, USA) version 20, and *P* \< 0.05 was considered statistically significant.

Restenosis interval was defined as the time from stent insertion to angiographic diagnosis of ISR.

RESULTS {#sec1-3}
=======

Baseline clinical findings and demographic and laboratory data are shown in [Table 1](#T1){ref-type="table"}.

###### 

Baseline findings in relation with nonin-stent restenosis and in-stent restenosis

  Variables                          NISR (202)            ISR (104)          *P*
  ---------------------------------- --------------------- ------------------ ---------
  Age (years)                        62.2±9.2              60.8±8.4           0.196
  Sex, *n* (%)                                                                
   Male                              138 (68.3)            77 (74.8)          0.101
   Female                            64 (31.7)             26 (25.2)          
  Hypertension, *n* (%)              131 (70.4)            55 (52.9)          0.051
  Diabetes mellitus, *n* (%)         70 (34.7)             63 (60.6)          \<0.001
  Positive smoking habit, *n* (%)    33 (16.7)             13 (13.0)          0.271
  Statin consumption, *n* (%)        185 (94.4)            93 (95.9)          0.235
  Aspirin consumption, *n* (%)       187 (95.4)            94 (95.9)          0.305
  Clopidogrel consumption, *n* (%)   171 (87.7)            88 (90.7)          0.234
  Stent type, *n* (%)                                                         
   Bare                              51 (39.5)             38 (60.3)          0.005
   Drug eluting                      78 (60.5)             25 (39.7)          
  SBP (mean±SD)                      125.4±16.6            123.2±12.5         0.352
  DBP (mean±SD)                      77.4±8.8              78±7.9             0.377
  FBG (mg/l)                         109.9±57.0            126.5±66.9         0.038
  TG (mg/l)                          108 (79-146)          127 (78.5-192.5)   0.039
  TC (mg/l)                          148.9±39.8            153.7±41.2         0.347
  LDL (mg/l)                         89.3±32.0             88.3±30.3          0.807
  HDL (mg/l)                         35.7±10.7             35±8.4             0.581
  hs-CRP (mg/l)                      2.3 (1.3-4.2)         3.46 (1.8-7.8)     0.006
  BMI (kg/m^2^), *n* (%)                                                      
   Normal                            72 (39.3)             29 (31.5)          0.333
   Overweight                        85 (46.4)             45 (48.9)          
   Obese                             26 (14.2)             18 (19.6)          
  Restenosis interval (months)       36.00 (12.00-60.00)   6.00 (4.00-8.00)   \<0.001

SBP=Systolic blood pressure; DBP=Diastolic blood pressure; FBG=Fasting blood glucose; TG=Triglyceride; TC=Total cholesterol; HDL=High-density lipoprotein; LDL=Low-density lipoprotein; hs-CRP=High sensitivity C-reactive protein; BMI=Body mass index; NISR=Nonin-stent restenosis; ISR=In-stent restenosis; SD=Standard deviation

FBG, serum TG, and serum hs-CRP levels were higher in the ISR cases than in the NISR cases (*P* \< 0.05), and a positive history of diabetes mellitus was significantly related to the presence of restenosis (*P* \< 0.001).

The bioactive agents used in drug-eluting stents reduce inflammation and smooth muscle cell proliferation and migration and consequently reduce the risk of restenosis. Patients treated with a bare-metal stent had a greater risk of restenosis in interval time between 1 month and 1 year after stent insertion than those treated with a drug-eluting stent (*P* = 0.005).

HRM genotyping results were determined using a Light Cycler 96 System, Roche, Germany software \[Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}\].
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A Chi-square test was used to assess the agreement of genotypes with the Hardy--Weinberg equilibrium, and there was no deviation from this for all three genotypes (*P* \> 0.05).

Based on SPSS analysis, allele frequencies were 0.66/0.44, 0.92/0.08, and 0.40/0.60 for *IL-10*-592C/A, *TNFα*-238G/A, and *ANXA5*-1247T/C, respectively. In a genetic association study on SNP with two alleles, patients have three genotypes. For *ANXA5* polymorphism, patients had CC, TC, and TT genotypes. T allele was more common in ISR group and may be susceptibility allele. We examined following genetic models: dominant model (TT + TC vs. CC), recessive model (TT vs. TC + CC), and additive model (TT vs. CC) and also for other two polymorphisms (IL-10 and TNFα). The most appropriate genetic models were dominant, recessive, and recessive for IL-10, TNFα, and ANXA5 SNPs, respectively \[[Table 2](#T2){ref-type="table"}\].

###### 

Distributions of interleukin-10, annexin A5, and tumor necrosis factor-alpha polymorphisms in association with in-stent restenosis using univariate logistic regression analysis

  Polymorphisms   Minor allele frequency   Genetic model   OR      95% CI        *P*
  --------------- ------------------------ --------------- ------- ------------- ------
  IL-10-592C/A    0.44                     Dominant        1.591   0.627-3.785   0.32
  TNFα-238G/A     0.08                     Recessive       1.44    0.724-2.754   0.29
  ANXA5-1247T/C   0.40                     Recessive       1.723   1.039-2.883   0.03

IL-10=Interleukin-10; TNFα=Tumor necrosis factor-alpha; ANXA5=Annexin A5; OR=Odds ratio; CI=Confidence interval

Initially, associations between different genotypes and restenosis were assessed using univariate logistic regression analysis without adjusting for other variants. There was a significant association between the *ANXA5* SNP and restenosis (OR: 1.72, 95% CI: 1.02--2.88, *P* = 0.03) but no other SNPs \[[Table 2](#T2){ref-type="table"}\]. In the final multiple logistic regression analysis with correction for covariates, there were no significant differences between the NISR and ISR groups for genotype distribution \[[Table 3](#T3){ref-type="table"}\].

###### 

Comparison of interleukin-10, annexin A5, and tumor necrosis factor-alpha polymorphism genotype between nonin-stent restenosis and in-stent restenosis groups using multiple logistic regression analysis

  Gene/polymorphisms   Allele   NISR (*n*=180)   ISR (*n*=93)   OR            95% CI        *P*
  -------------------- -------- ---------------- -------------- ------------- ------------- -----
  IL10/rs1800872       CC       79               40                           Reference=1   
  AC                   79       46               0.933          0.511-1.594   0.864         
  AA                   22       7                0.842          0.239-2.061   0.790         
  TNFα/rs361525        GG       154              74                           Reference=1   
  AG                   25       18               0.505          0.197-1.294   0.155         
  AA                   1        1                                                           
  AnxA5/rs6830321      CC       34               13                           Reference=1   
  TC                   87       37               0.577          0.166-2.014   0.389         
  TT                   59       43               0.476          0.134-1.686   0.250         

OR=Odds ratio; CI=Confidence interval; IL-10=Interleukin-10; TNFα=Tumor necrosis factor-alpha; ANXA5=Annexin A5; NISR=Non in-stent restenosis; ISR=In-stent restenosiss

DISCUSSION {#sec1-4}
==========

Angioplasty and stent implantation are associated with an inflammatory response because of the mechanical disruption of the coronary artery wall, and this stimulates smooth muscle cell migration and proliferation and finally neointimal hyperplasia.\[[@ref15]\] Neointimal hyperplasia is the most common cause of ISR, and 50% of the pathways associated with restenosis are related to inflammatory genes.\[[@ref14][@ref16]\] hs-CRP is an inflammatory biomarker and the relationship between serum hs-CRP as an independent factor and coronary restenosis has been reported previously.\[[@ref17][@ref18][@ref19]\]

Li *et al.* found in a meta-analysis study that high levels of serum CRP are accompanied by ISR, especially in patients with unstable angina.\[[@ref20]\] In our study, after logistic regression model, serum hs-CRP level was associated with ISR as an independent predictor.

The most common clinical factor that is associated with risk of restenosis is diabetes mellitus, especially patients who are treated with insulin.\[[@ref7]\] Endothelial dysfunction accompanies hyperglycemia, which is also a pro-inflammatory factor and increases production of cytokines and growth factors and consequently neointima formation.\[[@ref21]\] We found that diabetes mellitus and high FBG is positively related to ISR.

Kundi *et al.* in a case--control study showed the relationship between high TG level and ISR.\[[@ref22]\] In our study, TG level was associated with ISR.

Genetic factors play an important role in restenosis.\[[@ref7][@ref23]\] Polymorphisms in inflammatory-related genes have previously been reported to be associated with ISR.\[[@ref24][@ref25]\]

Some studies have shown that several polymorphisms in promoter region of the *IL-10* and *TNFα* gene can regulate the transcription of genes and consequently affect restenosis. In a GWA study (the GENDER project), Monraats *et al.* showed an association between three polymorphisms including the rs1800872, rs1800871, and rs1800896 of the IL-10 gene and coronary restenosis and Martínez-Ríos *et al.* also reported a relationship between these polymorphisms and restenosis in the Mexican population.\[[@ref26][@ref27]\] In our study, we investigated the relationship between IL-10-592C/A (rs1800872) SNP and angiographic restenosis and there was no significant association.

Monraats *et al.* reported two polymorphisms −238G\>A and −1031T\>C in the *TNF* gene were associated with coronary restenosis.\[[@ref27]\] However, Martínez-Ríos *et al.* and Koch *et al.* did not find an association between the −238G\>A SNP and restenosis.\[[@ref26][@ref28]\] In our study, there was no significant association between *TNFα* −238G\>A SNP and restenosis.

Ewing *et al.* found an association between rs4833229 and rs6830321 SNP in the *ANXA5* gene and risk of restenosis.\[[@ref29]\] Sampietro *et al.* also showed relationship between these polymorphisms and restenosis.\[[@ref30]\] In our study, there was a significant association between the rs4833229 SNP in *ANXA5* gene and restenosis in univariate logistic regression analysis, but there was no significant association in multiple logistic regression analysis.

CONCLUSION {#sec1-5}
==========

After adjustment for clinical variables, the genetic polymorphisms at the *IL-10, TNFα*, and *ANXA5* gene loci do not appear to be risk factors for ISR in our population. Our data suggest a significant association between diabetes mellitus, serum hs-CRP, and stent type with restenosis in logistic regression model and adjustment for other variables. Additional studies using a larger sample size are probably needed to evaluate the relationship of these polymorphisms and restenosis after coronary angioplasty.
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